Uno studio di BGB-16673 rispetto alla scelta dello investigatore nei partecipanti con leucemia linfocitica cronica precedentemente esposta a entrambi gli inibitori della tirosina chinasi di Bruton tirosina (BTK) e della leucemia/Linfoma 2 (BCL2) (CaDAnCe-302)
Uno studio di fase 3, aperto e randomizzato di BGB-16673 rispetto alla scelta dello investigatore (Idelalisib Plus Rituximab o Bendamustine Plus Rituximab o Venetoclax più Rituximab Ritrattamento) in pazienti con leucemia linfocitica cronica precedentemente esposta per BTK e BCL2 inibitore
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
CLL (chronic lymphocytic leukemia) and SLL (small lymphocytic lymphoma) are slow-growing blood cancers that affect the same type of white blood cell (called B lymphocytes). They are considered different forms of the same disease. CLL mainly occurs in the blood and bone marrow, while SLL mainly affects the lymph nodes.
Tacabrutideg is a type of medicine called a BTK degrader. BTK (Bruton's tyrosine kinase) is a protein that helps cancer cells survive. Tacabrutideg is designed to attach to the BTK protein and tag it for removal, so that the body's own cellular "clean-up" system breaks it down and clears it away. When more BTK is removed from the body, it interferes with the signals needed for the cancer cells to multiply and survive and may also help overcome resistance caused by certain changes in BTK.
The purpose of this study is to test if tacabrutideg is safe and if it works in adults with CLL or SLL. The main goal of the study is to find the amount of time participants live without their disease getting worse after starting the study treatment.
This study has two treatment groups. Participants will be randomly assigned by chance, to one of the treatment groups. Participants and the study doctors will know what treatment is received during the study.
The study will enroll approximately 250 adults at multiple centers worldwide with CLL or SLL. The overall time to participate in this study is 36 months. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and tumor and imaging tests.
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Study Director
- Numero di telefono: 1.877.828.5568
- Email: clinicaltrials@beonemed.com
Luoghi di studio
-
-
-
Caba, Argentina, CP1114
- Reclutamento
- FUNDALEU
-
Caba, Argentina, C1431
- Reclutamento
- CEMIC
-
Caba, Argentina, 1425
- Reclutamento
- Hospital Aleman
-
Ciudad Autonoma Buenos Aires, Argentina, 1413
- Reclutamento
- Hospital Italiano de Buenos Aires
-
Ciudad Autonoma Buenos Aires, Argentina, 1426
- Reclutamento
- Instituto Alexander Fleming (Iaf)
-
San Miguel de Tucumán, Argentina, 4000
- Reclutamento
- Cice 9 de Julio Sanatorio 9 de Julio
-
-
-
-
New South Wales
-
Concord, New South Wales, Australia, NSW 2139
- Reclutamento
- Concord Repatriation General Hospital
-
Gosford, New South Wales, Australia, NSW 2250
- Reclutamento
- Gosford Hospital
-
Port Macquarie, New South Wales, Australia, NSW 2444
- Reclutamento
- Port Macquarie Base Hospital
-
Randwick, New South Wales, Australia, NSW 2031
- Reclutamento
- Prince of Wales Hospital
-
-
Queensland
-
Toowoomba, Queensland, Australia, QLD 4350
- Reclutamento
- Toowoomba Hospital
-
-
South Australia
-
Bedford PK, South Australia, Australia, SA 5042
- Reclutamento
- Flinders Medical Centre
-
-
Victoria
-
Melbourne, Victoria, Australia, VIC 3004
- Reclutamento
- The Alfred Hospital
-
-
Western Australia
-
West Perth, Western Australia, Australia, WA 6005
- Reclutamento
- Perth Blood Institute
-
-
-
-
-
Belo Horizonte, Brasile, 30110-022
- Reclutamento
- CETUS
-
Brasília, Brasile, 70200-730
- Reclutamento
- Hospital Sirio Libanes Brasilia
-
Curitiba, Brasile, 81520-060
- Reclutamento
- Hospital Erasto Gaertner
-
Florianópolis, Brasile, 88020-210
- Reclutamento
- Centro de Ensino E Pesquisa Em Oncologia de Santa Catarina (Cepen)
-
Joinville, Brasile, 89201-260
- Reclutamento
- Instituto Joinvilense de Hematologia E Oncologia
-
Niterói, Brasile, 24020-096
- Reclutamento
- Complexo Hospitalar de Niteroi
-
Novo Hamburgo, Brasile, 93510-223
- Reclutamento
- Vida Hematologia
-
Porto Alegre, Brasile, 90110-270
- Reclutamento
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Rio de Janeiro, Brasile, 22250-040
- Reclutamento
- Oncoclinicas Rio de Janeiro Sa
-
Rio de Janeiro, Brasile, 22061-080
- Reclutamento
- Hospital Sao Lucas Dasa Oncologia
-
Salvador, Brasile, 41253-190
- Reclutamento
- Hospital Sao Rafael (Rede Dor)
-
São Paulo, Brasile, 05652-900
- Reclutamento
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brasile, 04014-002
- Reclutamento
- Instituto Brasileiro de Controle Do Cancer
-
São Paulo, Brasile, 01401-004
- Reclutamento
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
Vitória, Brasile, 29043-260
- Reclutamento
- Hospital Santa Rita de Cassia Afecc
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Reclutamento
- Juravinski Cancer Centre
-
London, Ontario, Canada, N6A 5W9
- Reclutamento
- London Health Sciences Centre
-
Ottawa, Ontario, Canada, K1H 8L6
- Reclutamento
- The Ottawa Hospital Cancer Centre
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Reclutamento
- Centre Integre de Sante Et de Services Sociaux de La Monteregie Centre
-
Montreal, Quebec, Canada, QC H3t 1E2
- Reclutamento
- Jewish General Hospital
-
SaintJerome, Quebec, Canada, J7Z 5T3
- Reclutamento
- Unite de Recherche Clinique Du Cisss Des Laurentides
-
-
-
-
-
Brno, Cechia, 625 00
- Reclutamento
- Fakultni Nemocnice Brno
-
Hradec Králové, Cechia, 500 03
- Reclutamento
- Fakultni Nemocnice Hradec Kralove
-
Ostrava, Cechia, 708 00
- Reclutamento
- Fakultni Nemocnice Ostrava
-
Prague, Cechia, 10000
- Reclutamento
- Vseobecna Fakultni Nemocnice V Praze
-
-
-
-
Busan Gwang'yeogsi
-
Seogu, Busan Gwang'yeogsi, Corea del Sud, 49201
- Reclutamento
- Dong A University Hospital
-
-
Daegu Gwang'yeogsi
-
Junggu, Daegu Gwang'yeogsi, Corea del Sud, 41944
- Reclutamento
- Kyungpook National University Hospital
-
-
Gyeonggi-do
-
IlsandongGu GoyangSi, Gyeonggi-do, Corea del Sud, 10408
- Reclutamento
- National Cancer Center (Korea)
-
-
Jeonnam-Gwangju S.M. City
-
HwasunGun, Jeonnam-Gwangju S.M. City, Corea del Sud, 58128
- Reclutamento
- Chonnam National University Hwasun Hospital
-
-
Seoul Teugbyeolsi
-
GangnamGu, Seoul Teugbyeolsi, Corea del Sud, 06351
- Reclutamento
- Samsung Medical Center
-
SeochoGu, Seoul Teugbyeolsi, Corea del Sud, 06591
- Reclutamento
- The Catholic University of Korea, Seoul St Marys Hospital
-
Seoul, Seoul Teugbyeolsi, Corea del Sud, 03080
- Reclutamento
- Seoul National University Hospital
-
-
-
-
-
Augsburg, Germania, 86156
- Reclutamento
- Universitatsklinikum Augsburg
-
Berlin, Germania, 10715
- Reclutamento
- Praxis Am Volkspark
-
Chemnitz, Germania, 09116
- Reclutamento
- Klinikum Chemnitz Ggmbh
-
Essen, Germania, 45122
- Reclutamento
- Universitatsklinikum Essen (Aor)
-
Frankfurt am Main, Germania, 60389
- Reclutamento
- Centrum Fur Haematologie Und Onkologie Bethanien
-
Freiburg im Breisgau, Germania, 79106
- Reclutamento
- Universitatsklinikum Freiburg I Br Klinik Fur Innere Medizin I
-
Hamburg, Germania, 20251
- Reclutamento
- Universitatsklinikum Hamburg Eppendorf
-
Heidelberg, Germania, 69120
- Reclutamento
- Universitatsklinikum Heidelberg
-
Homburg, Germania, 66421
- Reclutamento
- Universitatsklinikum Des Saarlandes
-
Koblenz, Germania, 56068
- Reclutamento
- Invo Institut Fur Versorgungsforschung in Der Onkologie
-
Leipzig, Germania, 04103
- Reclutamento
- Universitaetsklinikum Leipzig Aor
-
Münster, Germania, 48149
- Reclutamento
- Universitatsklinikum Munster Medizinische Klinik A
-
-
-
-
-
Kumamoto, Giappone, 860-8556
- Reclutamento
- Kumamoto University Hospital
-
Okayama, Giappone, 701-1192
- Reclutamento
- National Hospital Organization Okayama Medical Center
-
Osaka, Giappone, 545-8586
- Reclutamento
- Osaka Metropolitan University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Giappone, 464-8681
- Reclutamento
- Aichi Cancer Center Hospital Clinical Oncology
-
-
Chiba
-
Chiba, Chiba, Giappone, 260-8717
- Reclutamento
- Chiba Cancer Center
-
-
Ehime
-
Matsuyama, Ehime, Giappone, 791-0280
- Reclutamento
- Nho Shikoku Cancer Center
-
-
Hiroshima
-
Hiroshima, Hiroshima, Giappone, 730-8619
- Reclutamento
- Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, Giappone, 064-0804
- Reclutamento
- Aiiku Hospital
-
-
Hyōgo
-
AmagasakiCity, Hyōgo, Giappone, 660-8550
- Reclutamento
- Hyogo Prefectural Amagasaki General Medical Center
-
-
Kagoshima-ken
-
Kagoshima, Kagoshima-ken, Giappone, 890-8520
- Reclutamento
- Kagoshima University Hospital
-
-
Kyoto
-
KyotoShi, Kyoto, Giappone, 602-8566
- Reclutamento
- University Hospital, Kyoto Prefectural Univ of Medicine
-
-
Miyagi
-
Sendai, Miyagi, Giappone, 980-8574
- Reclutamento
- Tohoku University Hospital
-
-
Niigata
-
Niigata, Niigata, Giappone, 951-8520
- Reclutamento
- Niigata University Medical and Dental Hospital
-
-
Okayama-ken
-
Kurashikishi, Okayama-ken, Giappone, 710-8602
- Reclutamento
- Kurashiki Central Hospital
-
-
Osaka
-
Hirakata, Osaka, Giappone, 573-1191
- Reclutamento
- Kansai Medical University Hospital
-
Sakai, Osaka, Giappone, 590-0197
- Reclutamento
- Kindai University Hospital
-
-
Saitama
-
Kawagoeshi, Saitama, Giappone, 350-8550
- Reclutamento
- Saitama Medical Center
-
-
Tokyo
-
Bunkyoku, Tokyo, Giappone, 113-8677
- Reclutamento
- Tokyo Metropolitan Komagome Hospital
-
Shinagawaku, Tokyo, Giappone, 141-0022
- Reclutamento
- Ntt Medical Center Tokyo
-
-
-
-
-
Bari, Italia, 70124
- Reclutamento
- Irccs Istituto Tumori Giovanni Paolo Ii
-
Florence, Italia, 50134
- Reclutamento
- Aou Careggi, Servizio Sanitario Toscana
-
Milan, Italia, 20132
- Reclutamento
- Ospedale San Raffaele
-
Milan, Italia, 20122
- Reclutamento
- Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico
-
Naples, Italia, 80131
- Reclutamento
- Azienda Ospedaliera Universitaria Federico Ii
-
Novara, Italia, 28100
- Reclutamento
- Aou Maggiore Della Carita
-
Pavia, Italia, 27100
- Reclutamento
- Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
-
Perugia, Italia, 6129
- Reclutamento
- Ospedale Santa Maria Della Misericordia
-
Roma, Italia, 00168
- Reclutamento
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
-
Amsterdam, Olanda, 1081 HV
- Reclutamento
- Amsterdam Umc Vu Mc
-
-
-
-
-
Brzozów, Polonia, 36-200
- Reclutamento
- Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
-
Katowice, Polonia, 40-519
- Reclutamento
- Pratia Onkologia Katowice
-
Krakow, Polonia, 30-727
- Reclutamento
- Pratia McM Krakow
-
Lodz, Polonia, 93-510
- Reclutamento
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
-
Lublin, Polonia, 20-090
- Reclutamento
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
-
Wroclaw, Polonia, 50-367
- Reclutamento
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
-
Aberdeen, Regno Unito, AB25 2ZN
- Reclutamento
- Aberdeen Royal Infirmary
-
Birmingham, Regno Unito, B9 5SS
- Reclutamento
- Birmingham Heartlands Hospital
-
Bournemouth, Regno Unito, BH7 7DW
- Reclutamento
- The Royal Bournemouth and Christchurch Hospitals Nhs Foundation
-
London, Regno Unito, SW3 6JJ
- Reclutamento
- Royal Marsden Hospital
-
London, Regno Unito, NW1 2PG
- Reclutamento
- University College Hospital
-
Southampton, Regno Unito, SO16 6YD
- Reclutamento
- Southampton General Hospital
-
-
-
-
Arkansas
-
Jonesboro, Arkansas, Stati Uniti, 72401
- Reclutamento
- St Bernards Medical Center
-
-
California
-
Los Angeles, California, Stati Uniti, 90095-3075
- Reclutamento
- UCLA Department of Medicine Hematologyoncology
-
San Diego, California, Stati Uniti, 92103-2106
- Reclutamento
- Scripps Prebys Cancer Center
-
Whittier, California, Stati Uniti, 90602
- Reclutamento
- Pih Health Whittier Hospital
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80012-5405
- Reclutamento
- Rocky Mountain Cancer Centers (Williams) Usor
-
Golden, Colorado, Stati Uniti, 80401
- Reclutamento
- Intermountain Health Lutheran Hospital Cancer Center of Colorado
-
-
Florida
-
Fort Myers, Florida, Stati Uniti, 33912
- Reclutamento
- Florida Oncology and Hematology
-
Jacksonville, Florida, Stati Uniti, 32207-8432
- Reclutamento
- Baptist Md Anderson Cancer Center
-
Weston, Florida, Stati Uniti, 33331-3609
- Reclutamento
- Cleveland Clinic Florida
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322-1013
- Reclutamento
- Emory University Winship Cancer Institute
-
Atlanta, Georgia, Stati Uniti, 30342
- Reclutamento
- Northside Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70808-4365
- Reclutamento
- Our Lady of the Lake Hospital
-
-
Maryland
-
Bethesda, Maryland, Stati Uniti, 20817-7847
- Reclutamento
- American Oncology Partners of Maryland Pa
-
-
Michigan
-
Grand Rapids, Michigan, Stati Uniti, 49503-2560
- Reclutamento
- Corewell Health the Michigan Cancer Consortium
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455-0341
- Reclutamento
- University of Minnesota
-
-
Missouri
-
Chesterfield, Missouri, Stati Uniti, 63017
- Reclutamento
- St Lukes Center For Cancer Care
-
Springfield, Missouri, Stati Uniti, 65807-5288
- Reclutamento
- Oncology Hematology Associates
-
-
Montana
-
Billings, Montana, Stati Uniti, 59102-6746
- Reclutamento
- St Vincent Frontier Cancer Center
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68130-2042
- Reclutamento
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
-
-
New York
-
New York, New York, Stati Uniti, 10065-6800
- Reclutamento
- Memorial Sloan Kettering Cancer Center Mskcc
-
Shirley, New York, Stati Uniti, 11967
- Reclutamento
- New York Cancer and Blood Specialists
-
Syracuse, New York, Stati Uniti, 13210-2306
- Reclutamento
- Suny Upstate Medical University
-
Westbury, New York, Stati Uniti, 11590-5119
- Reclutamento
- Optum Medical Care, Pc
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106-1716
- Reclutamento
- University Hospitals
-
Dayton, Ohio, Stati Uniti, 45415
- Reclutamento
- Dayton Physician Network
-
-
Oregon
-
Eugene, Oregon, Stati Uniti, 97401
- Reclutamento
- Oncology Associates of Oregon Willamette Valley Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- Reclutamento
- West Penn Hospital
-
York, Pennsylvania, Stati Uniti, 17403-5049
- Reclutamento
- Cancer Care Associates of York
-
-
Texas
-
Temple, Texas, Stati Uniti, 76508-0001
- Reclutamento
- Baylor Scott and White Health Medical Center Temple
-
Tyler, Texas, Stati Uniti, 75702-7522
- Reclutamento
- Texas Oncology Tyler
-
-
-
-
-
Ankara, Turchia (Türkiye), 6500
- Reclutamento
- Gazi University
-
Ankara, Turchia (Türkiye), 06200
- Reclutamento
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
-
Balçova, Turchia (Türkiye), 35330
- Reclutamento
- Dokuz Eylul University
-
Dokuma, Turchia (Türkiye), 07025
- Reclutamento
- Antalya Memorial Hospital
-
Sakarya, Turchia (Türkiye), 54100
- Reclutamento
- Sakarya Training and Research Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
- Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
- Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI).
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
- Adequate liver function.
- Adequate blood clotting function.
Exclusion Criteria:
- Known prolymphocytic leukemia (defined per iwCLL 2018 as prolymphocytes comprising >55% of peripheral blood lymphocytes), or currently suspected or history of Richter's transformation within the last 5 years.
- Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 6 months.
- Known central nervous system involvement.
- Prior exposure to any BTK protein degraders.
- Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy.
- Clinically significant cardiovascular disease.
- Prior invasive fungal infection, except if patient agrees to receive secondary antifungal prophylaxis during the entire treatment period.
- Known contraindications to azole antifungal agents, including hypersensitivity reactions.
- Receiving systemic immunosuppressive therapy for a nonmalignant condition within 28 days before the first dose of study treatment.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Arm A: Tacabrutideg monotherapy
Participants will receive tacabrutideg once daily until any of the treatment discontinuation criteria are met |
Administered orally
Altri nomi:
|
|
Comparatore attivo: Arm B: Investigator's Choice
Participants will receive investigator's choice of idelalisib plus rituximab for CLL only or bendamustine plus rituximab, or venetoclax plus rituximab retreatment. |
Administered orally Administered intravenously Administered intravenously Administered orally |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-Free Survival (PFS) by Independent Review Committee (IRC)
Lasso di tempo: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL). |
Approximately 36 Months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS)
Lasso di tempo: Approximately 36 Months
|
OS is defined as time from the date of randomization to the date of death due to any cause. |
Approximately 36 Months
|
|
PFS by the Investigator Assessment
Lasso di tempo: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by the investigator using modified 2018 iwCLL criteria for participants with CLL and Lugano classification for participants with SLL |
Approximately 36 Months
|
|
Rate of Partial Response with Lymphocytosis (PR-L) or Higher Determined by IRC and by Investigator Assessment
Lasso di tempo: Approximately 36 Months
|
Rate of PR-L or higher is defined as the percentage of participants with a best overall response of CR, CRi, nPR, PR, or PR-L as assessed by the IRC or by the Investigator |
Approximately 36 Months
|
|
Duration of Response (DOR) by IRC and Investigator Assessment
Lasso di tempo: Approximately 36 Months
|
DOR is defined as the time from initial response to disease progression or death, whichever occurs first, as assessed by the IRC or by the investigator. |
Approximately 36 Months
|
|
Time to Next Anti-CLL/SLL Treatment (TTNT)
Lasso di tempo: Approximately 36 Months
|
TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment. |
Approximately 36 Months
|
|
Change from baseline in EORTC Quality of Life Questionnaire - Chronic Lymphocytic Leukemia Module 17 Items (QLQ-CLL17) Symptom Burden and Physical Condition Scales
Lasso di tempo: Approximately 24 Months
|
The symptom burden and physical condition will be measured by QLQ-CLL17. EORTC QLQ-CLL17 comprises 17 items grouped into 3 multi-item scales: 1) symptom burden, 2) physical condition/fatigue, and 3) worries/fears about health and functioning. Each question is rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much") and the recall period for all items is the past 7 days. The scores of each subscale are calculated based on the EORTC's protocol and then transformed to a 0 to 100 scale. Higher scores represent higher levels of symptom burden, physical condition/fatigue, or worries/fears about health and functioning. |
Approximately 24 Months
|
|
Progression-Free Survival (PFS) in Participants with Prior Exposure to Noncovalent Bruton Tyrosine Kinase Inhibitor(s) (ncBTKi) by IRC
Lasso di tempo: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 iwCLL criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL) for participants with prior exposure to ncBTKi. |
Approximately 36 Months
|
|
Overall Response Rate (ORR) by IRC and Investigator Assessment
Lasso di tempo: Approximately 36 Months
|
ORR is defined as the percentage of participants with best overall response of complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial response (PR) as assessed by the IRC or by the investigator. |
Approximately 36 Months
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Laboratory Abnormalities
Lasso di tempo: Approximately 36 Months
|
Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. |
Approximately 36 Months
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) Physical Functioning and Role Functioning Scales
Lasso di tempo: Approximately 24 Months
|
The EORTC QLQ-C30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales(fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1=Not at all (best) to 4=Very Much (worst) and 2 questions answered on a 7-point scale where 1=Very poor (worst) to 7=Excellent (best). Higher scores in GHS and functional scales indicate better quality of life. |
Approximately 24 Months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Study Director, BeOne Medicines
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Neoplasie
- Malattia cronica
- Attributi della malattia
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie ematologiche
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Leucemia, cellule B
- Leucemia, linfoide
- Leucemia
- Condizioni patologiche, segni e sintomi
- Malattie emiche e linfatiche
- Leucemia, linfocitica, cronica, cellule B
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti eterociclici
- Benzimidazoli
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Idrocarburi
- Acidi, aciclici
- Acidi carbossilici
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Butirati
- Anticorpi, monoclonali, derivati da murina
- Bendamustina cloridrato
- Rituximab
- Venetoclax
- Idelalisib
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- BGB-16673-302
- 2024-518893-15-00 (Ctis)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Periodo di condivisione IPD
See plan description
Criteri di accesso alla condivisione IPD
See plan description
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .